User menu

Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications

Bibliographic reference Elens, Laure ; Hesselink, Dennis A ; van Schaik, Ron H N ; van Gelder, Teun. Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications. In: Molecular Diagnosis and Therapy, Vol. 16, no. 6, p. 331-345 (2012)
Permanent URL http://hdl.handle.net/2078.1/125651
  1. Kronbach Thomas, Fischer Volker, Meyer Urs A, Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs, 10.1038/clpt.1988.87
  2. Picard N., Djebli N., Sauvage F.-L., Marquet P., Metabolism of Sirolimus in the Presence or Absence of Cyclosporine by Genotyped Human Liver Microsomes and Recombinant Cytochromes P450 3A4 and 3A5, 10.1124/dmd.106.012161
  3. Picard Nicolas, Rouguieg-Malki Koukeb, Kamar Nassim, Rostaing Lionel, Marquet Pierre, CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients : , 10.1097/tp.0b013e31820ae4ac
  4. Kamdem L. K., Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus, 10.1373/clinchem.2005.050047
  5. Amirimani B., Ning B., Deitz A.C., Weber B.L., Kadlubar F.F., Rebbeck T.R., Increased transcriptional activity of theCYP3A4*1B promoter variant, 10.1002/em.10199
  6. Fukushima-Uesaka Hiromi, Saito Yoshiro, Watanabe Hidemi, Shiseki Kisho, Saeki Mayumi, Nakamura Takahiro, Kurose Kouichi, Sai Kimie, Komamura Kazuo, Ueno Kazuyuki, Kamakura Shiro, Kitakaze Masafumi, Hanai Sotaro, Nakajima Toshiharu, Matsumoto Kenji, Saito Hirohisa, Goto Yu-ichi, Kimura Hideo, Katoh Masaaki, Sugai Kenji, Minami Narihiro, Shirao Kuniaki, Tamura Tomohide, Yamamoto Noboru, Minami Hironobu, Ohtsu Atsushi, Yoshida Teruhiko, Saijo Nagahiro, Kitamura Yutaka, Kamatani Naoyuki, Ozawa Shogo, Sawada Jun-ichi, Haplotypes ofCYP3A4 and their close linkage withCYP3A5 haplotypes in a Japanese population, 10.1002/humu.9210
  7. Wang D, Guo Y, Wrighton S A, Cooke G E, Sadee W, Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, 10.1038/tpj.2010.28
  8. Kuehl Peter, Zhang Jiong, Lin Yvonne, Lamba Jatinder, Assem Mahfoud, Schuetz John, Watkins Paul B., Daly Ann, Wrighton Steven A., Hall Stephen D., Maurel Patrick, Relling Mary, Brimer Cynthia, Yasuda Kazuto, Venkataramanan Raman, Strom Stephen, Thummel Kenneth, Boguski Mark S., Schuetz Erin, 10.1038/86882
  9. Hubbard Paul A., Shen Anna L., Paschke Rosemary, Kasper Charles B., Kim Jung-Ja P., NADPH-Cytochrome P450 Oxidoreductase : STRUCTURAL BASIS FOR HYDRIDE AND ELECTRON TRANSFER, 10.1074/jbc.m101731200
  10. Agrawal Vishal, Choi Ji Ha, Giacomini Kathleen M., Miller Walter L., Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase : , 10.1097/fpc.0b013e32833e0cb5
  11. Huang N., Agrawal V., Giacomini K. M., Miller W. L., Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations, 10.1073/pnas.0711621105
  12. Klein Kathrin, Thomas Maria, Winter Stefan, Nussler Andreas K., Niemi Mikko, Schwab Matthias, Zanger Ulrich M., PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo, 10.1038/clpt.2011.336
  13. Picard N., IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM, 10.1124/dmd.104.001651
  14. Bernard O., Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid, 10.1124/dmd.106.010553
  15. Gensburger O., Picard N., Marquet P., Effect of Mycophenolate Acyl-Glucuronide on Human Recombinant Type 2 Inosine Monophosphate Dehydrogenase, 10.1373/clinchem.2008.113936
  16. Shipkova Maria, Armstrong Victor W., Weber Lutz, Niedmann Paul D., Wieland Eberhard, Haley Jane, Tönshoff Burkhard, Oellerich Michael, Pharmacokinetics and Protein Adduct Formation of the Pharmacologically Active Acyl Glucuronide Metabolite of Mycophenolic Acid in Pediatric Renal Transplant Recipients : , 10.1097/00007691-200206000-00011
  17. Shipkova M, Wieland E, Schütz E, Wiese C, Niedmann P.D, Oellerich M, Armstrong V.W, The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes, 10.1016/s0041-1345(00)02424-6
  18. Girard Hugo, Court Michael H, Bernard Olivier, Fortier Louis-Charles, Villeneuve Lyne, Hao Qin, Greenblatt David J, von Moltke Lisa L, Perussed Louis, Guillemette Chantal, Identification of common polymorphisms in the promoter of the UGT1A9 gene : evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver, 10.1097/01.fpc.0000114754.08559.27
  19. Bernard O., THE MAIN ROLE OF UGT1A9 IN THE HEPATIC METABOLISM OF MYCOPHENOLIC ACID AND THE EFFECTS OF NATURALLY OCCURRING VARIANTS, 10.1124/dmd.32.8.775
  20. Huang Yue-Hua, Galijatovic Alema, Nguyen Nghia, Geske Donald, Beaton Deirdre, Green Judith, Green Mark, Peters Wilbert H., Tukey Robert H., Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3 : , 10.1097/00008571-200206000-00004
  21. Djebli Nassim, Picard Nicolas, Rérolle Jean-Philippe, Meur Yann Le, Marquet Pierre, Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients : , 10.1097/fpc.0b013e32801430f8
  22. Duguay Y, A novel functional polymorphism in the uridine diphosphate–glucuronosyltransferase 2B7 promoter with significant impact on promoter activity, 10.1016/j.clpt.2003.10.006
  23. Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood. 1992;80(6):1528–36.
  24. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268(9):6077–80.
  25. Kimchi-Sarfaty C., Oh J. M., Kim I.-W., Sauna Z. E., Calcagno A. M., Ambudkar S. V., Gottesman M. M., A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity, 10.1126/science.1135308
  26. Wang Danxin, Johnson Andrew D., Papp Audrey C., Kroetz Deanna L., Sadée Wolfgang, Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability : , 10.1097/01.fpc.0000178311.02878.83
  27. Hitzl Monika, Drescher Siegfried, van der Kuip Heiko, Schäffeler Elke, Fischer Joachim, Schwab Matthias, Eichelbaum Michel, Fromm Martin F., The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells : , 10.1097/00008571-200106000-00003
  28. Siegsmund M., Association of the P-Glycoprotein Transporter MDR1C3435T Polymorphism with the Susceptibility to Renal Epithelial Tumors, 10.1097/01.asn.0000019412.87412.bc
  29. Westley I. S., ROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE, 10.1124/dmd.105.006122
  30. Picard N, Yee S W, Woillard J-B, Lebranchu Y, Le Meur Y, Giacomini K M, Marquet P, The Role of Organic Anion–Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics, 10.1038/clpt.2009.205
  31. Staatz Christine E, Tett Susan E, Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients : , 10.2165/00003088-200746010-00002
  32. August Phyllis, Suthanthiran Manikkam, Transforming growth factor beta and progression of renal disease, 10.1046/j.1523-1755.64.s87.15.x
  33. Rudnicki Michael, Mayer Gert, Significance of genetic polymorphisms of the renin–angiotensin–aldosterone system in cardiovascular and renal disease, 10.2217/14622416.10.3.463
  34. Node K., Anti-inflammatory Properties of Cytochrome P450 Epoxygenase-Derived Eicosanoids, 10.1126/science.285.5431.1276
  35. Zeldin Darryl C., Moomaw Cindy R., Jesse Nate, Tomer Kenneth B., Beetham Jeffrey, Hammock Bruce D., Wu Shu, Biochemical Characterization of the Human Liver Cytochrome P450 Arachidonic Acid Epoxygenase Pathway, 10.1006/abbi.1996.0229
  36. HESSELINK D, VANGELDER T, VANSCHAIK R, BALK A, VANDERHEIDEN I, VANDAM T, VANDERWERF M, WEIMAR W, MATHOT R, Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the and genes, 10.1016/j.clpt.2004.08.022
  37. Tang Hui-Lin, Ma Lu-Lin, Xie Hong-Guang, Zhang Ting, Hu Yong-Fang, Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis : , 10.1097/fpc.0b013e32833ccd56
  38. Elens Laure, van Schaik Ron H, Panin Nadtha, de Meyer Martine, Wallemacq Pierre, Lison Dominique, Mourad Michel, Haufroid Vincent, Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients, 10.2217/pgs.11.90
  39. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012;22(5):373–80.
  40. Shuker Nauras, Bouamar Rachida, Weimar Willem, van Schaik Ron.H.N., van Gelder Teun, Hesselink Dennis A., ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation, 10.1016/j.cca.2011.09.040
  41. Staatz Christine E., Goodman Lucy K., Tett Susan E., Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II : , 10.2165/11317550-000000000-00000
  42. Staatz Christine E., Goodman Lucy K., Tett Susan E., Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I : , 10.2165/11317350-000000000-00000
  43. Capron Arnaud, Mourad Michel, De Meyer Martine, De Pauw Luc, Eddour Djamila Chaib, Latinne Dominique, Elens Laure, Haufroid Vincent, Wallemacq Pierre, CYP3A5andABCB1polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation, 10.2217/pgs.10.43
  44. Crettol Séverine, Venetz Jean-Pierre, Fontana Massimiliano, Aubert John-David, Ansermot Nicolas, Fathi Marc, Pascual Manuel, Eap Chin B., Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients : , 10.1097/fpc.0b013e3282f7046f
  45. Elens Laure, Capron Arnaud, Kerckhove Valérie Van, Lerut Jan, Mourad Michel, Lison Dominique, Wallemacq Pierre, Haufroid Vincent, 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation : , 10.1097/fpc.0b013e3282e9a533
  46. Salama Noha N., Yang Ziping, Bui T.o.t., Ho Rodney J.Y., MDR1 haplotypes significantly minimize intracellular uptake and transcellular P‐gp substrate transport in recombinant LLC‐PK1 cells, 10.1002/jps.20717
  47. Woodahl E. L., Multidrug Resistance Gene G1199A Polymorphism Alters Efflux Transport Activity of P-Glycoprotein, 10.1124/jpet.104.065383
  48. Bandur Stepan, Petrasek Jan, Hribova Petra, Novotna Eva, Brabcova Irena, Viklicky Ondrej, Haplotypic Structure of ABCB1/MDR1 Gene Modifies the Risk of the Acute Allograft Rejection in Renal Transplant Recipients : , 10.1097/tp.0b013e318187c4d1
  49. Hesselink Dennis A, Bouamar Rachida, van Gelder Teun, The Pharmacogenetics of Calcineurin Inhibitor–Related Nephrotoxicity : , 10.1097/ftd.0b013e3181e44244
  50. Hauser I. A., ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation, 10.1681/asn.2004100882
  51. Woillard J-B, Rerolle J-P, Picard N, Rousseau A, Guillaudeau A, Munteanu E, Essig M, Drouet M, Le Meur Y, Marquet P, Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up, 10.1038/clpt.2010.62
  52. Cattaneo D., Ruggenenti P., Baldelli S., Motterlini N., Gotti E., Sandrini S., Salvadori M., Segoloni G., Rigotti P., Donati D., Perico N., Remuzzi G., , ABCB1 Genotypes Predict Cyclosporine-Related Adverse Events and Kidney Allograft Outcome, 10.1681/asn.2008080819
  53. Hauser I A, Kruck S, Gauer S, Nies A T, Winter S, Bedke J, Geiger H, Hoefeld H, Kleemann J, Asbe-Vollkopf A, Engel J, Burk O, Schwab M, Schaeffeler E, Human Pregnane X Receptor Genotype of the Donor but Not of the Recipient Is a Risk Factor for Delayed Graft Function After Renal Transplantation, 10.1038/clpt.2011.346
  54. Goto Maki, Masuda Satohiro, Kiuchi Tetsuya, Ogura Yasuhiro, Oike Fumitaka, Okuda Masahiro, Tanaka Koichi, Inui Ken-ichi, CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation : , 10.1097/01.fpc.0000114747.08559.49
  55. Haufroid Vincent, Mourad Michel, Van Kerckhove Val??rie, Wawrzyniak Jeremie, De Meyer Martine, Eddour Djamila Chaib, Malaise Jacques, Lison Dominique, Squifflet Jean-Paul, Wallemacq Pierre, The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients : , 10.1097/00008571-200403000-00002
  56. Haufroid V., Wallemacq P., VanKerckhove V., Elens L., De Meyer M., Eddour D. C., Malaise J., Lison D., Mourad M., CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study, 10.1111/j.1600-6143.2006.01518.x
  57. Hesselink Dennis A., van Schaik Ron H.N., van Agteren Madelon, de Fijter Johannes W., Hartmann Anders, Zeier Martin, Budde Klemens, Kuypers Dirk R.J., Pisarski Przemyslav, Meur Yann Le, Mamelok Richard D., van Gelder Teun, CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients : , 10.1097/fpc.0b013e3282f75f88
  58. Hesselink D, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, 10.1016/s0009-9236(03)00168-1
  59. Kuypers D R J, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y, CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients, 10.1038/sj.clpt.6100216
  60. MacPhee Iain A.M., Fredericks Salim, Mohamed Maha, Moreton Michelle, Carter Nicholas D., Johnston Atholl, Goldberg Lawrence, Holt David W., Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians : , 10.1097/01.tp.0000151766.73249.12
  61. Thervet Eric, Anglicheau Dany, King Barry, Schlageter Marie-H??l??ne, Cassinat Bruno, Beaune Philippe, Legendre Christophe, Daly Ann K., Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 : , 10.1097/01.tp.0000090753.99170.89
  62. Tsuchiya Norihiko, Satoh Shigeru, Tada Hitoshi, Li Zhenhua, Ohyama Chikara, Sato Kazunari, Suzuki Toshio, Habuchi Tomonori, Kato Tetsuro, Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients : , 10.1097/01.tp.0000137789.58694.b4
  63. van Gelder T, Hesselink D A, Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?, 10.1038/clpt.2010.42
  64. Zhao Y., Song M., Guan D., Bi S., Meng J., Li Q., Wang W., Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus, 10.1016/j.transproceed.2005.01.077
  65. Zheng HongXia, Webber Steven, Zeevi Adriana, Schuetz Erin, Zhang Jiong, Bowman Pamela, Boyle Gerard, Law Yuk, Miller Susan, Lamba Jatinder, Burckart Gilbert J., Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms, 10.1034/j.1600-6143.2003.00077.x
  66. Zheng HongXia, Zeevi Adriana, Schuetz Erin, Lamba Jatinder, McCurry Kenneth, Griffith Bartley P., Webber Steven, Ristich Julianne, Dauber James, Iacono Aldo, Grgurich Wayne, Zaldonis Diana, McDade Kevin, Zhang Jiong, Burckart Gilbert J., Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism, 10.1177/0091270003262108
  67. Tang Hui-Lin, Xie Hong-Guang, Yao Yao, Hu Yong-Fang, Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers : , 10.1097/fpc.0b013e32834a48ca
  68. Birdwell Kelly A., Grady Ben, Choi Leena, Xu Hua, Bian Aihua, Denny Josh C., Jiang Min, Vranic Gayle, Basford Melissa, Cowan James D., Richardson Danielle M., Robinson Melanie P., Ikizler Talat Alp, Ritchie Marylyn D., Stein Charles Michael, Haas David W., The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients : , 10.1097/fpc.0b013e32834e1641
  69. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87(6):721–6.
  70. Tavira Beatriz, Garciá Eliecer Coto, Díaz-Corte Carmen, Ortega Francisco, Arias Manuel, Torres Armando, Díaz Juan M., Selgas Rafael, López-Larrea Carlos, Campistol Josep M., Alvarezca Victoria, Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes, 10.1515/cclm.2011.143
  71. Elens L., Bouamar R., Hesselink D. A., Haufroid V., van der Heiden I. P., van Gelder T., van Schaik R. H. N., A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients, 10.1373/clinchem.2011.165613
  72. de Jonge Hylke, Metalidis Christoph, Naesens Maarten, Lambrechts Diether, Kuypers Dirk RJ, The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients, 10.2217/pgs.11.77
  73. Li Yi, Hu Xin, Cai Bei, Chen Jie, Bai Yangjuan, Tang Jiangtao, Liao Yun, Wang Lanlan, Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients, 10.1016/j.trim.2012.03.006
  74. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol. 1996;50(1):52–9.
  75. Naesens M., Lerut E., de Jonge H., Van Damme B., Vanrenterghem Y., Kuypers D. R. J., Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts, 10.1681/asn.2009020192
  76. De Meyer Martine, Haufroid Vincent, Elens Laure, Fusaro Fabio, Patrono Damiano, De Pauw Luc, Kanaan Nada, Goffin Eric, Mourad Michel, Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation, 10.1016/j.jss.2012.06.070
  77. Anglicheau Dany, Le Corre Delphine, Lechaton Sophie, Laurent-Puig Pierre, Kreis Henri, Beaune Philippe, Legendre Christophe, Thervet Eric, Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy, 10.1111/j.1600-6143.2005.00745.x
  78. Djebli Nassim, Rousseau Annick, Hoizey Guillaume, Rerolle Jean-Philippe, Toupance Olivier, Le Meur Yann, Marquet Pierre, Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant Recipients : , 10.2165/00003088-200645110-00007
  79. MEUR Y, DJEBLI N, SZELAG J, HOIZEY G, TOUPANCE O, REROLLE J, MARQUET P, CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients, 10.1016/j.clpt.2006.03.012
  80. Miao Li-Yan, Huang Chen-Rong, Hou Jian-Quan, Qian Mei-Ying, Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients, 10.1002/bdd.577
  81. Mourad Michel, Mourad Georges, Wallemacq Pierre, Garrigue Val??rie, Van Bellingen Christophe, Van Kerckhove Val??rie, De Meyer Martine, Malaise Jacques, Eddour Djamila Chaib, Lison Dominique, Squifflet Jean Paul, Haufroid Vincent, Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids : , 10.1097/01.tp.0000174131.47469.d2
  82. Woillard J, Kamar N, Rostaing L, Marquet P, Picard N. Effect of a new functional CYP3A4 polymorphism on sirolimus in vitro metabolism and kidney transplant recipients trough levels [abstract]. 7e Congrès de Physiologie, de Pharmacologie et de Thérapeutique. 2012 Apr 4–6; Dijon.
  83. Elens L, Mourad M, Delefortrie Q, Mourad G, De Meyer M, Wallemacq P, et al. Impact of CYP3A4*22 allele on sirolimus dose requirement in kidney transplant patients [abstract]. 24th International Congress of the Transplantation Society. 2012 Jul 15–19; Berlin.
  84. Baldelli Sara, Merlini Simona, Perico Norberto, Nicastri Annalisa, Cortinovis Monica, Gotti Eliana, Remuzzi Giuseppe, Cattaneo Dario, C-440T/T-331C polymorphisms in theUGT1A9gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation, 10.2217/14622416.8.9.1127
  85. Johnson L’Aurelle A., Oetting William S., Basu Saonli, Prausa Susie, Matas Arthur, Jacobson Pamala A., Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors, 10.1007/s00228-008-0501-y
  86. Kuypers Dirk R.J., de Jonge Hylke, Naesens Maarten, de Loor Henriette, Halewijck Evelyne, Dekens Marc, Vanrenterghem Yves, Current target ranges of mycophenolic acid exposure and drug-related adverse events: A 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients, 10.1016/j.clinthera.2008.04.014
  87. KUYPERS D, NAESENS M, VERMEIRE S, VANRENTERGHEM Y, The impact of uridine diphosphate–glucuronosyltransferase 1A9 () gene promoter region single-nucleotide polymorphisms and on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients, 10.1016/j.clpt.2005.06.007
  88. Lévesque E, Delage R, Benoit-Biancamano M-O, Caron P, Bernard O, Couture F, Guillemette C, The Impact of UGT1A8, UGT1A9, and UGT2B7 Genetic Polymorphisms on the Pharmacokinetic Profile of Mycophenolic Acid After a Single Oral Dose in Healthy Volunteers, 10.1038/sj.clpt.6100073
  89. Sánchez-Fructuoso A.I., Maestro M.L., Calvo N., Viudarreta M., Pérez-Flores I., Veganzone S., De la Orden V., Ortega D., Arroyo M., Barrientos A., The Prevalence of Uridine Diphosphate-Glucuronosyltransferase 1A9 (UGT1A9) Gene Promoter Region Single-Nucleotide Polymorphisms T-275A and C-2152T and Its Influence on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Patients, 10.1016/j.transproceed.2009.06.038
  90. van Schaik R H N, van Agteren M, de Fijter J W, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der Werf M, Mamelok R, van Gelder T, UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients, 10.1038/clpt.2009.83
  91. van Agteren M, Armstrong VW, van Schaik RH, de Fijter H, Hartmann A, Zeier M, et al. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. Ther Drug Monit. 2008;30(4):439–44.
  92. Woillard Jean-Baptiste, Rerolle Jean-Philippe, Picard Nicolas, Rousseau Annick, Drouet Mireille, Munteanu Eliza, Essig Marie, Marquet Pierre, Le Meur Yann, Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele : Pharmacogenetics of mycophenolate-induced diarrhoea, 10.1111/j.1365-2125.2010.03625.x
  93. Yang Jae Wook, Lee Puay Hoon, Hutchinson Ian V, Pravica Vera, Shah Tariq, Min David I, Genetic Polymorphisms of MRP2 and UGT2B7 and Gastrointestinal Symptoms in Renal Transplant Recipients Taking Mycophenolic Acid : , 10.1097/ftd.0b013e3181b1dd5e
  94. Geng F, Jiao Z, Dao YJ, Qiu XY, Ding JJ, Shi XJ, et al. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals. Clin Chim Acta. 2012;413(7–8):683–90.
  95. Hamada A., Sissung T., Price D. K., Danesi R., Chau C. H., Sharifi N., Venzon D., Maeda K., Nagao K., Sparreboom A., Mitsuya H., Dahut W. L., Figg W. D., Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer, 10.1158/1078-0432.ccr-07-4118
  96. Miura Masatomo, Satoh Shigeru, Inoue Kazuyuki, Kagaya Hideaki, Saito Mitsuru, Inoue Takamitsu, Suzuki Toshio, Habuchi Tomonori, Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients, 10.1007/s00228-007-0380-7
  97. Gensburger Olivier, Van Schaik Ron H.N., Picard Nicolas, Le Meur Yannick, Rousseau Annick, Woillard Jean-Baptiste, Van Gelder Teun, Marquet Pierre, Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil : , 10.1097/fpc.0b013e32833d8cf5
  98. Kagaya Hideaki, Miura Masatomo, Saito Mitsuru, Habuchi Tomonori, Satoh Shigeru, Correlation of IMPDH1 Gene Polymorphisms with Subclinical Acute Rejection and Mycophenolic Acid Exposure Parameters on Day 28 after Renal Transplantation : MPA PK, ACUTE REJECTION AND IMPDH1 POLYMORPHISMS, 10.1111/j.1742-7843.2010.00542.x
  99. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R, Fu J, Shah T, Pravica V, Hutchinson IV, Burckart GJ, IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients, 10.1038/sj.clpt.6100347
  100. Grinyó Josep, Vanrenterghem Yves, Nashan Björn, Vincenti Flavio, Ekberg Henrik, Lindpaintner Klaus, Rashford Michelle, Nasmyth-Miller Clare, Voulgari Athina, Spleiss Olivia, Truman Matthew, Essioux Laurent, Association of four DNA polymorphisms with acute rejection after kidney transplantation, 10.1111/j.1432-2277.2008.00679.x
  101. Jacobson Pamala A., Schladt David, Oetting William S., Leduc Robert, Guan Weihau, Matas Arthur J., Lamba Vishal, Mannon Roslyn B., Julian Bruce A., Israni Ajay, Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation : , 10.1097/tp.0b013e318200e971
  102. Bouamar Rachida, Elens Laure, Shuker Nauras, van Schaik Ron H.N., Weimar Willem, Hesselink Dennis A., van Gelder Teun, Mycophenolic Acid-Related Anemia and Leucopenia in Renal Transplant Recipients Are Related to Genetic Polymorphisms in CYP2C8 : , 10.1097/tp.0b013e3182488bb4
  103. MacPhee Iain A. M., Fredericks Salim, Tai Tracy, Syrris Petros, Carter Nicholas D., Johnston Atholl, Goldberg Lawrence, Holt David W., The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation, 10.1111/j.1600-6143.2004.00435.x
  104. Rivory L. P., Qin H., Clarke S. J., Eris J., Duggin G., Ray E., Trent R. J., Bishop J. F., Frequency of cytochrome P 450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance, 10.1007/s002280000166
  105. Singh Ranjana, Srivastava Aneesh, Kapoor Rakesh, K. Sharma Raj, D. Mittal Rama, Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India, 10.1007/s00210-009-0415-y
  106. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 2001;47(6):1048–52.
  107. Hu Y.-F., Tu J.-H., Tan Z.-R., Liu Z.-Q., Zhou G., He J., Wang D., Zhou H.-H., Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects, 10.1080/00498250601149206
  108. Zeng Yong, He Yi-jing, He Fu-yuan, Fan Lan, Zhou Hong-hao, Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects, 10.1038/aps.2009.27
  109. Anglicheau D, CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation, 10.1016/j.clpt.2004.01.009
  110. Hu Yong-Fang, Qiu Wen, Liu Zhao-Qian, Zhu Li-Jun, Liu Zhong-Qi, Tu Jiang-Hua, Wang Dan, Li Zhi, He Jun, Zhong Gan-Ping, Zhou Gan, Zhou Hong-Hao, EFFECTS OF GENETIC POLYMORPHISMS OF CYP3A4, CYP3A5 AND MDR1 ON CYCLOSPORINE PHARMACOKINETICS AFTER RENAL TRANSPLANTATION, 10.1111/j.1440-1681.2006.04492.x
  111. Kreutz Reinhold, Z??rcher Heiko, Kain Silke, Martus Peter, Offermann Gerd, Beige Joachim, The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients : , 10.1097/00008571-200410000-00004
  112. Kreutz R, Bolbrinker J, van der Sman-de Beer F, Boeschoten E W, Dekker F W, Kain S, Martus P, Sietmann A, Friedrichs F, Stoll M, Offermann G, Beige J, CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine, 10.1038/sj.tpj.6500488
  113. Fanta Samuel, Niemi Mikko, Jönsson Siv, Karlsson Mats O., Holmberg Christer, Neuvonen Pertti J., Hoppu Kalle, Backman Janne T., Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms : , 10.1097/fpc.0b013e3282f3ef72
  114. Fanta Samuel, Jönsson Siv, Karlsson Mats O., Niemi Mikko, Holmberg Christer, Hoppu Kalle, Backman Janne T., Long-Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect ofNR1I2Polymorphism, 10.1177/0091270009348223
  115. Press Rogier R., Ploeger Bart A., den Hartigh Jan, van der Straaten T., van Pelt Hans, Danhof Meindert, de Fijter Hans, Guchelaar Henk-Jan, Explaining variability in ciclosporin exposure in adult kidney transplant recipients, 10.1007/s00228-010-0810-9
  116. Jacobson PA, Schladt D, Israni A, Oetting WS, Lin YC, Leduc R, et al. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. Transplantation. 2012;93(6):624–31.
  117. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I, CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients, 10.1038/sj.clpt.6100039
  118. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, André J L, Garaix F, Bensman A, Fakhoury M, Jacqz-Aigrain E, Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients, 10.1038/clpt.2009.210
  119. Benkali Khaled, Prémaud Aurelie, Picard Nicolas, Rérolle Jean-Philippe, Toupance Olivier, Hoizey Guillaume, Turcant Alain, Villemain Florence, Le Meur Yannick, Marquet Pierre, Rousseau Annick, Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients : , 10.2165/11318080-000000000-00000
  120. Cho J.-H., Huh S., Kwon T.-G., Choi J.-Y., Hur I.-K., Lee E.-Y., Park S.-H., Kim Y.-L., Kim C.-D., Association of C-509T and T869C Polymorphisms of Transforming Growth Factor-β1 Gene With Chronic Allograft Nephropathy and Graft Survival in Korean Renal Transplant Recipients, 10.1016/j.transproceed.2008.06.047
  121. Gervasini Guillermo, Garcia Montserrat, Macias Rosa María, Cubero Juan Jose, Caravaca Francisco, Benitez Julio, Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation : Pharmacogenetics of tacrolimus, 10.1111/j.1432-2277.2012.01446.x
  122. Glowacki François, Lionet Arnaud, Hammelin Jean-Philippe, Labalette Myriam, Provôt François, Hazzan Marc, Broly Franck, Noël Christian, Cauffiez Christelle, Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients : , 10.2165/11587050-000000000-00000
  123. Joy M. S., Hogan S. L., Thompson B. D., Finn W. F., Nickeleit V., Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity, 10.1093/ndt/gfm133
  124. Metalidis Christoph, Lerut Evelyne, Naesens Maarten, Kuypers Dirk R.J., Expression of CYP3A5 and P-glycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity : , 10.1097/tp.0b013e3182177502
  125. Sam Wai-Johnn, Chamberlain Christine E., Lee Su-Jun, Goldstein Joyce A., Hale Douglas A., Mannon Roslyn B., Kirk Allan D., Yi Hon Yuen, Associations of ABCB1 3435C>T and IL-10-1082G>A Polymorphisms With Long-Term Sirolimus Dose Requirements in Renal Transplant Patients : , 10.1097/tp.0b013e3182384ae2
  126. Moes Dirk Jan A.R., Press Rogier R., den Hartigh Jan, van der Straaten Tahar, de Fijter Johan W., Guchelaar Henk-Jan, Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients : , 10.2165/11599710-000000000-00000
  127. Jiao Zheng, Ding Jun-jie, Shen Jie, Liang Hui-qi, Zhong Long-jin, Wang Yi, Zhong Ming-kang, Lu Wei-yue, Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9, 10.1111/j.1365-2125.2008.03109.x
  128. Kagaya Hideaki, Inoue Kazuyuki, Miura Masatomo, Satoh Shigeru, Saito Mitsuru, Tada Hitoshi, Habuchi Tomonori, Suzuki Toshio, Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients, 10.1007/s00228-006-0248-2
  129. Zhang W.-X., Chen B., Jin Z., Yu Z., Wang X., Chen H., Mao A., Cai W., Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients, 10.1080/00498250802488585
  130. Naesens Maarten, Kuypers Dirk R. J., Verbeke Kristin, Vanrenterghem Yves, Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients : , 10.1097/01.tp.0000235533.29300.e7
  131. Sombogaard Ferdi, van Schaik Ron H.N., Mathot Ron A., Budde Klemens, van der Werf Marloes, Vulto Arnold G., Weimar Willem, Glander Petra, Essioux Laurent, van Gelder Teun, Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism : , 10.1097/fpc.0b013e32832f5f1b
  132. Wang Jian, Zeevi Adriana, Webber Steve, Girnita Diana M., Addonizio Linda, Selby Rick, Hutchinson Ian V., Burckart Gilbert J., A novel variant L263F in human inosine 5???-monophosphate dehydrogenase 2 is associated with diminished enzyme activity : , 10.1097/fpc.0b013e328012b8cf